Venetoclax Tablets
for oral use Initial U.S. Approval: 2016
Venetoclax tablets is “used to treat Chronic Lymphocytic Leukemia (CLL) or in combination with azacitidine or low dose cytarabine for untreated Acute Myeloid Leukemia (AML)“. VENCLEXTA tablets is a “prescription medicine”. It is available in “form and strength” Tablets: 10 mg, 50 mg, 100 mg. VENCLEXTA for injection can be obtained in India upon request.
To inquire about the VENCLEXTA (venetoclax tablets) “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Name: Venclyxto
Active substance: Venetoclax
Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell
Marketing Authorisation: 04/12/2016.
AUTHORISED: This medicine is authorised for use in the European Union.
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)